The Swiss drugmaker is licensing an investigational obesity candidate from the Chinese biotech, adding to its push into the weight loss drug race.
Recap by typeshit. Full story at Reuters on MSN.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Its October check of 21 US telehealth programs found compounded semaglutide at a $175 median, with a $79 sale low, counting memberships in the all-in price.
The poster says nausea and vomiting rates in the UBT251 trial look identical and may make it seem easier to tolerate than rivals. It's one user's analysis.
Loading…